X0306 4 2022-06-17 0 0001557746 Aclaris Therapeutics, Inc. ACRS 0001172252 SCHIFF ANDREW N C/O ACLARIS THERAPEUTICS, INC. 640 LEE ROAD, SUITE 200 WAYNE PA 19087 1 0 0 0 Common Stock 2022-06-17 4 S 0 19565 15.1428 D 0 D Common Stock 634455 I By Aisling Capital IV LP These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 16, 2022. The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $15.00 to $15.35, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The reportable securities are owned directly by Aisling Capital IV, LP ("Aisling"), and held indirectly by Aisling Capital Partners IV, LP ("Aisling GP"), as general partner of Aisling, Aisling Capital Partners IV LLC ("Aisling Partners"), as general partner of Aisling GP, and each of the individual managing members of Aisling Partners. The individual managing members (collectively, the "Managers") of Aisling Partners are Dr. Andrew Schiff and Steve Elms. Aisling GP, Aisling Partners, and the Managers share voting and dispositive power over the shares directly held by Aisling. Dr. Schiff disclaims beneficial ownership of these securities and this report is not an admission that he is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of his pecuniary interest therein. /s/ Mark Ballantyne, Attorney-in-Fact 2022-06-21